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Abstract
Introduction: For expansion of human mesenchymal stem cells (MSCs), autologous human serum is safer than
fetal bovine serum in clinical situations. One of the problems with the use of autologous human serum is that its
proliferative effect on MSCs varies widely between donors. The threefold goals of this study were: (1) to
demonstrate an improved method for preparing human serum; (2) to identify growth factors predictive of
proliferative potential; and (3) to identify a cytokine to promote MSC proliferation in human serum.
Methods: Fresh blood was collected using a closed bag system containing glass beads. The bag was shaken at 20
°C for 30 minutes for rapid preparation, or kept stationary at 4 °C for 24 hours for slow preparation. Passage 0
synovial MSCs derived from four donors were cultured with 10 % conventional rapid preparation serum or modified
slow preparation serum from four different donors. To perform the colony-forming unit assay, synovial MSCs were
cultured in these serums. The protein expression profile in serum was analyzed using cytokine array. The candidate
proteins were speculated from the correlation between the colony-forming ability and protein expression. As an
evaluation of the candidate proteins, proliferation ability, surface marker phenotype and differentiation capability of
synovial MSCs were examined.
Results: Compared with rapid preparation serum, slow preparation serum resulted in a significantly higher total
colony number and twofold higher expression levels of nine proteins (angiopoietin-1, BDNF, EGF, ENA-78, IGFBP-2,
platelet-derived growth factor (PDGF)-AA, PDGF-AB/BB, RANTES and TfR). Colony number was positively correlated
with PDGF-AA/AB concentrations. Exogenous PDGF-AA significantly promoted proliferation of synovial MSCs,
whereas PDGF receptor (PDGFR) inhibitor decreased it. Addition of PDGFs or PDGFR inhibitor did not affect surface
epitopes of synovial MSCs. Pretreatment with PDGFs or PDGFR inhibitor did not affect chondrogenic, adipogenic, or
calcification potentials of synovial MSCs.
Conclusion: Slow preparation serum contained higher concentrations of PDGF-AA/AB and increased the colony
formation number of synovial MSCs. PDGF-AA/AB were indicators of the proliferative potential of human serum.
Exogenous PDGF-AA increased proliferation of synovial MSCs without alteration of surface epitopes and
differentiation potentials.
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Introduction
Mesenchymal stem cells (MSCs) are used clinically in
the field of regenerative medicine [1, 2]. Though MSCs
are often expanded with fetal bovine serum (FBS) [3–5],
autologous human serum is safer than FBS in clinical sit-
uations because it avoids the risk of immune reactions
and contamination with pathogens such as prion or zoo-
notic viruses [6–8]. MSCs derived from synovium have a
high chondrogenic potential and synovial MSCs ex-
panded with autologous human serum are used clinically
for cartilage regeneration [1, 9–11]. In this setting, au-
tologous human serum is separated after fresh blood is
shaken at 20 °C for 30 minutes in a plastic bag contain-
ing glass beads [1, 12]. However, this preparation
method is not the best. The first objective of this study
was to show a better method of preparing human serum
with more proliferative potential.
One of the problems with the use of autologous hu-
man serum is that its proliferative effect on MSCs varies
widely between donors [13]. Human serum with inferior
quality may result in too low a yield of MSCs to be
transplanted in clinical situations. To obtain a sufficient
number of MSCs with absolute certainty, it is essential
to predict the proliferative potential of human serum. In
addition, since serum contains a great variety of growth
factors, attention should be paid to those that are desir-
able. The second objective of this study was to identify
growth factors that predict the proliferative potential of
synovial MSCs expanded in human serum.
When inferior quality of human serum is a concern,
rescuing the serum is required in clinical situations. One
possibility is to add a growth factor to the serum, in
which case this growth factor should not affect MSC
properties. The third objective of this study was to iden-
tify a cytokine to promote proliferation of synovial MSCs
cultured by human serum.
Methods
Collection of human serum
The present study was approved by the Medical Re-
search Ethics Committee of Tokyo Medical and Dental
University (approved No. 1431) and all human study
subjects provided informed consent. Fresh blood was
collected from four healthy male volunteers (32–36
years) using a closed bag system (JMS Co., Ltd, Hiro-
shima, Japan) [14]. The bag containing glass beads was
shaken at 20 °C for 30 minutes for rapid preparation, or
kept stationary at 4 °C for 24 hours for slow preparation,
and then serum in each group was separated (Fig. 1).
These sera was filtered through a 0.45-μm nylon filter
(Thermo Fisher Scientific, Inc., Waltham, MA, USA)
and stored at –20 °C until use.
Quantification of cytokine expression levels
The relative levels of cytokines in sera were analyzed
using a Human XL Cytokine Array (R&D Systems, MN,
USA) according to the manufacturer’s instructions. The
positive spots were semi-quantitatively evaluated by the
Image Lab software (Bio-Rad Laboratories, Richmond,
CA, USA). The serum levels of platelet-derived growth
factor (PDGF)-AA, PDGF-AB and PDGF-BB were mea-
sured by sandwich enzyme-linked immunosorbent assay
(ELISA; DAA00B, DHD00C and DBB00; R&D Systems)
following the manufacturer’s protocol.
Fig. 1 Schema of rapid preparation and slow preparation for sera
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Synovial MSCs
Human synovium was harvested from the knees of
seven donors (71–83 years) with osteoarthritis during
total knee arthroplasty. Synovium was digested in a
solution of 3 mg/mL collagenase (Sigma-Aldrich
Japan, Tokyo, Japan) in Hanks’ balanced salt solution
(HBSS; Gibco, Waltham, MA, USA) at 37 °C. After 3
hours, the digested cells were filtered through a 70-
μm cell strainer (Greiner Bio-One GmbH, Fricken-
hausen, Germany). The cells were cultured in human
serum culture medium, α-minimum essential medium
(α-MEM; Gibco) supplemented with 1 % antibiotic-
antimycotic (Gibco) and with 10 % human serum
without heat inactivation in a cell culture incubator
(Astec, Fukuoka, Japan) set 37 °C and 5 % CO2. The
cells were counted with a disposable cell counting
plate (One Cell Inc., Shiga, Japan) to determine the
number of cells.
Colony formation and proliferation of synovial MSCs
For colony formation assay, passage 0 synovial MSCs
from four donors were plated on six-well plates at 100
cells/10 cm2 well and cultured with 10 % rapid or slow
preparation serum from four other donors. The well was
stained with crystal violet at 14 days and the colony
number was counted. For proliferation assay, passage 1
synovial MSCs from three donors were plated on six-
well plates at 100 cells/cm2 well and cultured with 10 %
rapid preparation serum from one other donor. The cells
were harvested with 0.25 % trypsin and 1 mM EDTA
(Gibco) at 37 °C for 5 minutes and counted with a cell-
counting plate.
Supplementation of growth factors
The culture medium, α-MEM containing 10 % human
rapid preparation serum, was supplemented with 5 ng/
mL PDGF-AA, PDGF-AB, PDGF-BB (R&D Systems), 10
nM Crenolanib as a PDGF receptor (PDGFR) α and β
inhibitor (MedChem Express, NJ, USA) or vehicle (di-
methyl sulfoxide; Wako, Tokyo, Japan) as a control.
Flow cytometric analysis
Cultured synovial MSCs from three donors at passage 1
were harvested using a cell-dissociation buffer. Cells
were suspended in HBSS at a density of 5 × 105 cells/mL
and stained for 30 minutes on ice with the antibodies
CD31-PE-Cy7 (Becton, Dickinson and Company; BD,
Franklin Lakes, NJ, USA), CD45-APC-H7 (Biolegend, San
Diego, CA, USA), CD44-APC-H7 (BD), CD73-BV421
(BD), CD90-PE (BD), CD105-PerCP-Cy5.5 (BD), CD140a-
BV421 (BD), CD140b-PerCP-Cy5.5 (BD), CD146-FITC
(BD) and CD271-APC (Miltenyi Biotec) for cell surface
analysis. Flow cytometric analysis of the cell surface was
performed by a triple-laser FACS Verse™ system (BD).
Differentiation assay
Cultured synovial MSCs from three donors at passage 1
were harvested using 0.25 % trypsin and 1 mM EDTA.
For adipogenic differentiation, adherent cells were cul-
tured in adipogenic induction medium (Lonza, Basel,
Switzerland), which was changed every 3–4 days. After
21 days, oil red-o staining (Muto Pure Chemicals,
Tokyo, Japan) confirmed the differentiation of these cells
into adipocytes [15]. To quantify the amount of oil red-
o, the stained oil droplets were extracted by 2-propanol
(Wako, Tokyo, Japan) and oil red-o stain in extraction
buffer was determined by measuring the optical density
of the solution at 510 nm [16].
For osteogenic differentiation, 100 cells were trans-
ferred to a 100-mm dish and cultured for 14 days in cul-
ture medium. Adherent cells were cultured in
osteogenic induction medium containing 50 μg/mL as-
corbic acid 2-phosphate (Wako), 10 nM dexamethasone
(Wako) and 10 mM β-glycerophosphate (Sigma-Al-
drich), which was changed every 3–4 days. After 21 days,
the differentiation of these cells into osteoblasts was
assessed by alizarin red staining (Merck Millipore, Biller-
ica, MA, USA) [17]. To quantify the amount of alizarin
red, the deposition was extracted by 10 % (w/v) cetylpyr-
idinium chloride (Sigma-Aldrich) in 10 mM sodium
phosphate (pH 7.0) at room temperature for 1 hour and
the alizarin red stain in extraction buffer was determined
by measuring the optical density of the solution at 560
nm [16].
For chondrogenic differentiation, 2.5 × 105 cells were
transferred to a 15-mL tube (BD Falcon) and cultured in
chondrogenic induction medium containing 10 ng/mL
transforming growth factor-β3 (Miltenyi Biotec Japan,
Tokyo, Japan) and 500 ng/mL bone morphogenetic pro-
tein 2 (Medtronic), which was changed every 3–4 days.
After 21 days, chondrogenic differentiated cells were an-
alyzed by toluidine blue (Wako) staining.
Statistical analysis
All data were statistically evaluated by analysis of vari-
ance with GraphPad Prism 6 (GraphPad Software, La
Jolla, CA, USA). Data are expressed as mean ± SD. Each
statistical analysis method is described in the legend.
Two-tailed P values < 0.05 were considered to be
significant.
Results
Colony number of synovial MSCs by rapid and slow
preparation serum
Synovial MSCs formed cell colonies 14 days after culture
with conventional rapid preparation serum (Fig. 2a). The
use of slow preparation serum, a modified method, re-
sulted in a significantly higher number of cell colonies in
three of four donors (Fig. 2b). The colony number
Mizuno et al. Stem Cell Research & Therapy  (2015) 6:243 Page 3 of 11
obtained by rapid preparation serum was 7.4 ± 3.7 and
was 14.5 ± 5.5 by slow preparation serum on average
when sera from four donors and synovial MSCs derived
from another four donors were used.
Cytokine expression levels in rapid and slow preparation
serum
We analyzed eight serum samples from four donors by
cytokine arrays and detected 43 positive spots among
102 proteins examined (Fig. 3a, Table 1). A heat map
showing the pixel density of these spots demonstrated
that, for most cytokines detected, expression levels
depended on serum preparation methods (Fig. 3b). Ac-
cording to a heat map for the ratio of each protein
expression in slow preparation serum to that in rapid
preparation serum, the ratio was twice as high in nine
cytokines (angiopoietin-1, BDNF, EGF, ENA-78, IGFBP-
2, PDGF-AA, PDGF-AB/BB, RANTES and TfR) at least
in one donor per protein (Fig. 3c).
Correlation between colony number of MSCs and PDGF
concentrations in sera
A heat map of r-values, obtained after correlation ana-
lysis between cytokine expression levels and colony for-
mation numbers, revealed that r-values were higher than
0.5 for PDGF-AA and AB/BB (Fig. 4a). PDGF-AA and
PDGF-AB concentrations measured by ELISA were
higher in slow preparation serum than in rapid
Fig. 2 Colony number of synovial mesenchymal stem cells (MSCs) by rapid and slow preparation serum. a Representative wells stained with
crystal violet. Sera derived from four donors and synovial MSCs derived from other four donors were used. b Quantification of colony number.
Data are shown as mean ± SD (n = 6 in a minimum unit). *p < 0.001 by two-way analysis of variance with repeated measures
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preparation serum in all four donors, while PDGF-BB
concentration measured by ELISA was not (Fig. 4b).
There were positive correlations between colony num-
bers and concentrations for both PDGF-AA (r = 0.66)
and PDGF-AB (r = 0.63) (Fig. 4c).
Effect of exogenous PDGFs on proliferation of synovial
MSCs
To examine the effect of PDGFs on proliferation of syn-
ovial MSCs, they were cultured with PDGF-AA, -AB,
-BB, Crenolanib (PDGFR α and β inhibitor) or vehicle
(dimethyl sulfoxide). PDGFs and PDGFR inhibitor did
not affect the morphology of synovial MSCs (Fig. 5a).
PDGF-AA significantly increased and PDGFR inhibitor
significantly decreased the proliferation of synovial
MSCs (Fig. 5b).
Effect of exogenous PDGFs on surface markers of
synovial MSCs
Synovial MSCs expressed CD44, CD73 and CD90 at
high rates (over 90 %), CD105 and CD140b at a moder-
ate rate (over 50 %), CD140a and CD271 at low rates
(approximately 20 %), and did not express CD31, CD45
and CD146. Exogenous PDGFs and PDGFR inhibitor did
not affect these surface markers (Fig. 6).
Effect of exogenous PDGFs on differentiation potentials
of synovial MSCs
Synovial MSCs were pretreated with PDGFs and PDGFR
inhibitor, and then differentiated into cartilage. Irrespect-
ive of exogenous PDGFs, cartilage pellets were spherical
(Fig. 7a), and the matrix showed a purple color after
toluidine blue staining (Fig. 7b). Pretreatment with
Fig. 3 Cytokine expressions in rapid and slow preparation serum. a Representative images of cytokine arrays. Each antibody is spotted in
duplicate on a nitrocellulose membrane. Spots for PDGF-AA are surrounded with red squares. b Heat map for cytokine expression level in rapid
and slow preparation sera in four donors. c Heat map for ratio of cytokine expression level in slow preparation serum to cytokine expression level
in rapid preparation serum. See Table 1 for a list of proteins
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PDGFs did not affect pellet weight (Fig. 7c), an indicator
of chondrogenic potential.
After adipogenic induction, synovial MSCs contained
lipid shown as red after oil red-o staining irrespective of
exogenous PDGFs (Fig. 8a). Pretreatment with PDGFs
did not affect adipogenic potential evaluated by optical
density for oil red-o (Fig. 8b).
After calcification induction, synovial MSCs formed
alizarin red positive colonies irrespective of exogenous
PDGFs (Fig. 9a). Pretreatment with PDGFs did not affect
calcification potential evaluated by optical density for ali-
zarin red (Fig. 9b).
Discussion
In this study we showed that slow preparation serum
formed more cell colonies than rapid preparation serum.
Fresh blood was collected in a closed bag containing
glass beads. The bag was shaken at 20 °C for 30 minutes
for rapid preparation, or kept stationary at 4 °C for 24
hours for slow preparation. These stationary conditions
have been shown to promote the release of growth fac-
tors from platelets, such as PDGFs [18, 19]. Proper man-
agement of this human serum isolation protocol would
be able to comply with good gene, cellular and tissue-
based products manufacturing practice (GCTP) for clin-
ical or commercial use, since this method is very simple.
Low stability of human serum may cause growth fail-
ure of MSCs and discontinuation of clinical cell trans-
plantation. In the present study, by analyzing the
relationships between serum protein profiles and colony
formation of synovial MSCs, we demonstrated that
PDGF-AA and PDGF-AB were the growth factors pre-
dictive of the proliferative potential of human serum.
We also showed that supplementation with PDGF-AA
improved the proliferation of MSCs. If the concentration
of PDGF-AA in serum is low, the addition of PDGF-AA
will compensate for the quality of the serum. The in-
tractable problems caused by individual differences in
human serum may thus be resolved.
Exogenous PDGFs did not affect MSC-related surface
marker expressions. Positive rate for CD140a (PDGFRα)
was around 20 % and this was lower than that in our
previous reports [12]. Our recent experiments indicated
that the positive rate for CD140a decreased by trypsin
(manuscript in preparation). In our current study, treat-
ment with trypsin might affect CD140a expression of
human synovial MSCs.
Pretreatment with PDGFs did not affect chondrogenic
potential of synovial MSCs, though PDGF signaling was






BAFF; B-cell activating factor belonging to the tumor necrosis factor family MMP-9; matrix metalloproteinase-9
BDNF; brain-derived neurotrophic factor Myeloperoxidase
Complement component C5/C5a Osteopontin
CD14 Platelet-derived growth factor (PDGF)-AA
Chitinase 3-like 1 PDGF-AB/BB
Complement factor D PF4; CXCL4
CRP; C-reactive protein RANTES; regulated on activation, normal T cell expressed and secreted,
CCL5
Cystatin C RBP4; retinol-binding protein 4
DPPIV; dipeptidyl-peptidase IV, CD26 Resistin; adipose tissue-specific secretory factor (ADSF)
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ENA-78; epithelial-derived neutrophil-activating peptide 78, CXCL5 SHBG; sex hormone-binding globulin
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Fig. 4 Correlation between colony number of synovial MSCs and platelet-derived growth factor (PDGF) concentrations in sera. a Heat map for
r-value in correlation analysis between cytokine expression levels measured by cytokine array and colony formation number of synovial MSCs.
*p < 0.05 and r > 0.5 by Pearson correlation coefficient. b Concentration of PDGF isoforms in serum measured by ELISA. c Correlation analysis
between concentrations of PDGF isoforms in sera and colony formation numbers of synovial MSCs. See Table 1 for a list of proteins
Fig. 5 Effect of exogenous platelet-derived growth factors (PDGFs) on proliferation of synovial MSCs. a Representative cell morphology. Synovial
MSCs were plated at 100 cells/ cm2 and cultured for 10 days in the presence of PDGF isoforms or PDGF receptor (PDGFR) inhibitor. b Fold
increase of synovial MSCs. Data are shown as mean ± SD (n = 9). *p < 0.05, versus rapid preparation with vehicle by one-way analysis of variance
followed by Dunnett's multiple comparisons
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significant in chondrogenesis [20]. Pretreatment with
PDGFs also did not affect adipogenic and calcification
potential of synovial MSCs. This is possibly because hu-
man serum includes various growth factors that help to
compensate differentiation ability. Therefore, it is
estimated that PDGF supplementation would not ad-
versely affect outcomes after transplantation in vivo.
This is the most important point for regenerative medi-
cine in clinical situations that place great value on safety
[21]. The concentrations of PDGFs needed to examine
Fig. 6 Effect of exogenous platelet-derived growth factors (PDGFs) on surface markers of synovial MSCs. Synovial MSCs derived from three donors
were plated at 100 cells/cm2 and cultured for 10 days in the presence of PDGF isoforms and PDGF receptor (PDGFR) inhibitor. Data are shown
as mean ± SD
Fig. 7 Effect of pretreatment of platelet-derived growth factors (PDGFs) on chondrogenesis of synovial MSCs. a Representative macroscopic
appearance. Synovial MSCs derived from three donors were pretreated with PDGFs, and then differentiated into cartilage pellets (n = 6 in each
donor). b Histological sections stained with toluidine blue. c Wet weight of pellets. Data are shown as mean ± SD (n = 18). PDGFR PDGF receptor
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the effect of exogenous PDGFs on synovial MSCs were
set up to be similar to human serum.
We propose three limitations in this study. First, we
did not examine the proliferative effect of cells other
than synovial MSCs, though the effects of PDGF-AA
and -AB can be expected in MSCs derived from other
tissues, such as bone marrow and adipose tissue, based
on their PDGFR expression [22, 23]. Second, we focused
on 43 cytokines detected with a cytokine array kit that is
designed to determine the selected 102 cytokines but did
not examine the effect of other cytokines not included
in this kit. Indeed, synovial MSCs cultured with PDGFR
inhibitor still increased, suggesting that other cytokines
such as EGF [24] compensated for proliferative effects.
Fig. 8 Effect of pretreatment of platelet-derived growth factors (PDGFs) on adipogenesis of synovial MSCs. a Representative cell morphology
stained with oil red-o. Synovial MSCs were pretreated with PDGFs, and then differentiated into adipocytes. b Relative optical density for oil red-o.
Data are shown as mean ± SD (n = 4). PDGFR PDGF receptor
Fig. 9 Effect of pretreatment of platelet-derived growth factors (PDGFs) on calcification of synovial MSCs. a Representative culture dishes stained
with alizarin red. Synovial MSCs were pretreated with PDGFs, and then calcified. b Relative optical density for alizarin red. Data are shown as
mean ± SD (n = 6). PDGFR PDGF receptor
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Third, human serum derived from only one donor was
used to examine the effects of exogenous PDGFs. Donor
variety of responsiveness to PDGFs may not be ignored.
Conclusions
Slow preparation serum contained higher concentrations
of PDGF-AA/AB and increased the colony formation
number of synovial MSCs. PDGF-AA/AB were indica-
tors of the proliferative potential of human serum. The
addition of PDGF-AA increased proliferation of synovial
MSCs without alteration of surface epitopes and differ-
entiation potentials.
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